Published in Cancer Weekly, May 8th, 1995
A new study conducted by researchers at Toronto-Sunnybrook Regional Cancer Center suggests that the anti-cancer drug paclitaxel (Taxol), when combined with another agent (cisplatin), is a cost-effective addition to current therapies used to treat advanced ovarian cancer. The cost-effectiveness of treatment with paclitaxel/cisplatin in advanced ovarian cancer (AOC) compares favorably to many other widely accepted treatment strategies for diseases such as breast cancer, heart disease, diabetes and AIDS.
The study was presented by Allan Covens, M.D., Division of Gynecologic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.